Gene Expression Analysis in Drug Discovery Market Size, Share and Trends Analysis, By Product and Service (Reagents and Consumables, Instruments, and Service), By Type (Bulk RNA Sequence, Single Cell Analysis, and Spatial Transcriptomics), By Molecule Type, By Therapeutic Area, By Application, By End-Use, and By Region, Forecast 2025-2032

Gene Expression Analysis in Drug Discovery Market Overview and Key Insights:

The gene expression analysis in drug discovery market size reached USD 2,394.5 million in 2024 and is expected to register a revenue CAGR of 9.4% during the forecast period. Gene expression analysis is the process of determining the pattern of genes expressed at the genetic transcription level, under certain conditions or in each cell. Gene expression analysis is a vital method used in drug development, life science research, and bioproduction optimization.

Market Drivers:

Growing prevalence of chronic and genetic diseases is a key driver of revenue growth in the gene expression analysis in drug discovery market. According to the International Diabetes Federation (IDF), approximately 589 million persons aged 20 to 79 have diabetes in 2024. By 2050, one out of every eight persons, or nearly 853 million, would have diabetes, a 46% rise. More than four in five persons (81%) with diabetes live in low- and middle-income nations. More than 90% of diabetics have type 2 diabetes, which is caused by socioeconomic, demographic, environmental, and genetic variables. Global diabetes-related health expenditure topped one trillion US dollars in 2024, up from USD 966 billion in 2021.

Advancements in genomic technologies is another key driver driving the market revenue growth over the forecasted period. It is becoming more apparent that gene expression analysis is critical in uncovering the intricate molecular complexities that underpin biological systems. The introduction of bioinformatics has resulted in a revolutionary transformation in the field of gene expression analysis, providing researchers with a vast repertoire of robust analytical methodologies and cutting-edge tools designed specifically to decipher the complex tapestry of large-scale gene expression datasets. The introduction of revolutionary technologies including as Sequence Analysis of Gene Expression (SAGE), microarrays, and RNA-Seq has ushered in a new era of gene expression investigations with unparalleled granularity and resolution, allowing researchers to delve into the finer nuances of gene expression phenomenon.

On July 2024, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the release of the ddSEQTM Single-Cell 3′ RNA-Seq Kit with Omnition v1.1 analytic software for single-cell transcriptome and gene expression studies. The ddSEQ Single-Cell 3′ RNA-Seq Kit, which is designed to be used with Bio-Rad’s droplet-based single-cell isolation system, the ddSEQ Cell Isolator, produces high-quality single-cell 3′ RNA-Seq libraries in a fast, efficient, and cost-effective workflow, allowing researchers to easily conduct single-cell gene expression and regulation analyses.

Market Opportunity:

Integration with Artificial Intelligence (AI) & machine learning acts as an opportunity for the gene expression analysis in drug discovery market. Computational analytic approaches, like as machine learning, have a substantial impact on genetics and medicine. High-throughput gene expression analysis techniques, such as microarray technology and RNA sequencing, generate massive volumes of data. The current applications of genetics in clinical research may benefit from data from multiple modalities. Data sparsity or class imbalance is a major challenge when analyzing gene expression data from complex disorders.

On May 2025, Illumina Inc. has revealed PromoterAI, a new artificial intelligence program that properly identifies pathogenic regulatory genetic variations in the human genome’s noncoding regions. PromoterAI, which is built on cutting-edge deep learning neural networks, provides remarkable precision when interpreting promoter variations. Clinical researchers can use PromoterAI to analyze whole-genome sequencing (WGS) data to better understand the etiology and drug target potential for rare genetic illnesses, common diseases, and oncology.

Recent Trends:

Emerging trends include adoption of Single-Cell RNA Sequencing (scRNA-seq), spatial transcriptomics, cloud-based bioinformatics platforms, CRISPR-based functional genomics, and Non-Coding RNA (ncRNA) profiling.

The rapid advancement of next-generation sequencing (NGS) technology in recent years has yielded many significant insights into complex biological systems, ranging from cancer genomics to varied microbial ecosystems. Single-cell RNA sequencing (scRNA-seq), for example, can reveal complicated and rare cell populations, as well as regulatory links between genes and the trajectories of different cell lineages during development.

ScRNA-seq and related computational tools have greatly aided the advancement of single-cell transcriptomics. Continuous advancement in scRNA-seq technology, combined with advances in bioinformatics methodologies, will considerably facilitate biological and clinical research, as well as provide deep insights into cell gene expression heterogeneity and dynamics.

Restraints & Challenges:

Large-scale genomic research has the potential to expand understanding of human cancer biology and improve diagnosis, prognosis, and therapy options. Technological differences and developments have had an impact on reproducibility. Statistical challenges in linking a high number of variables to a small number of observations have imposed additional limits.

Mapped reads are more difficult to analyze than continuous microarray data because count data must be modeled using discrete distributions that have not previously been used for gene expression data analysis. Furthermore, dimensionality issues arise since there are frequently fewer repeat samples available than for microarray datasets.

Product and Service Segment Insights and Analysis:

Based on the product and service, the gene expression analysis in drug discovery market is segmented into reagents and consumables, instruments, and service.

Instruments segment contributed the largest market share in 2024. Instruments is further sub segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), DNA microarrays, and others. NGS enables the rapid sequencing of millions of DNA fragments at once, enabling complete insights into genome structure, genetic variants, gene expression levels, and epigenetic alterations. Integrating DNA methylation profiles with RNA-seq data can help discover differentially methylated regions (DMRs) linked to gene expression variations. The combination of histone modification and chromatin accessibility data with RNA-seq enables the identification of regulatory regions associated with unique gene expression patterns and the investigation of epigenetic regulatory processes.

On December 2023, CCM Biosciences, a diverse biotechnology firm, announced the formation of its business unit CCM 5Prime Sciences, which will focus on the development and deployment of patented technology in the field of DNA biology. 5Prime’s technological platform consists of numerous patent-protected, globally commercialized formulations and methods for molecular cloning, next-generation DNA sequencing, and molecular diagnostics.

Therapeutic Area Segment Insights and Analysis:

Based on the therapeutic area, the gene expression analysis in drug discovery market is segmented into neurology, diabetes, oncology, and others.

Oncology segment contributed the largest market share in 2024. According to the International Agency for Research on Cancer (IARC), in 2022, there will be approximately 20 million new instances of cancer (including nonmelanoma skin cancers (NMSCs), as well as 9.7 million cancer-related deaths. According to estimates, one in every five men and women will get cancer at some point in their lives, with one in every nine men and one in every twelve women dying from it. Lung cancer was the most often diagnosed cancer in 2022, accounting for about 2.5 million new cases, or one in every eight malignancies worldwide, followed by cancers of the female breast.

On June 2025, Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, has announced the launch of its Single-Cell Genotype and Targeted Gene Expression assay, which expands the Tapestri Platform’s capabilities to become the only commercial solution that provides simultaneous genotype and targeted gene expression profiling from over 10,000 single cells. The multi-modal assay serves three key purposes: understanding treatment resistance, creating next-generation T-cell therapeutics, and enhancing patient selection in clinical development.

Application Segment Insights and Analysis:

Based on the application, the gene expression analysis in drug discovery market is segmented into in biomarker discovery, drug target identification and validation, toxicogenomics, pharmacogenomics, and others.

Biomarker discovery segment contributed the largest market share in 2024. High-throughput transcriptome methods are increasingly being utilized to screen environmental contaminants in vitro, identifying molecular targets and providing mechanistic background for regulatory assessment. Gene expression biomarkers are developed by comparing global gene expression levels in cells or tissues exposed to substances known to affect the factor of interest.

Understanding the key characteristics of each cancer type is critical for deciphering molecular pathways, identifying novel biomarkers, and uncovering possible therapeutic targets. Explainable AI algorithms provide a powerful tool for identifying feature importance and comprehending the role of genes in cancer prediction.

Geographical Outlook:

Gene expression analysis in drug discovery market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Gene Expression Analysis in Drug Discovery Market:

North America is registered to have largest market share in gene expression analysis in drug discovery market in 2024. This is mainly due to the growing prevalence of chronic and genetic diseases and technological advancements in genomic technologies. According to the American Cancer Society, lung cancer (both small cell and non-small cell) is the second most frequent cancer among men and women in the United States. Estimates for lung cancer in the United States in 2025 are approximately 226,650 new cases of lung cancer (110,680 males and 115,970 women) and approximately 124,730 fatalities from lung cancer (64,190 males and 60,540 women).

On July 2024, Biostate AI has introduced Total RNA Sequencing, a method that uses patent-pending Barcode-Integrated Reverse Transcription (BIRT) to examine all types of RNA, including non-coding RNA species. The company’s RNA sequencing and analysis tools technology enables researchers to obtain a better knowledge of gene expression and regulation, which leads to insights into disease causes and potential treatment targets. Biostate AI intends to collaborate with academic researchers, hospital biorepositories, and pharmaceutical and biotech companies to use its technologies for scalable multi-omic data collecting and AI training.

Asia Pacific Gene Expression Analysis in Drug Discovery Market:

Asia Pacific is registered the fastest growth rate during the forecasted period driven by growing prevalence of chronic and genetic diseases, rising demand for personalized medicine, and development of companion diagnostics and biomarkers. According to the World Health Organization (WHO), in India, an estimated 77 million persons over the age of 18 have diabetes (type 2), with almost 25 million prediabetics. It is anticipated that by 2030, India would have 100 million patients with this condition. India is undergoing an epidemiological transition, which includes changes in population distribution, fertility rates, life expectancy, and the primary causes of death.

On August 2023, BostonGene, a leading provider of AI-based molecular and immune profiling solutions, NEC Corporation, a leader in IT, network, and AI technologies, and Japan Industrial Partners, a leading Tokyo-based private equity firm, announced the formation of BostonGene Japan Inc., a joint venture aimed at advancing personalized medicine and dramatically improving patient outcomes. The new firm will use BostonGene’s high-complexity molecular technology and innovative biocomputational algorithms, such as BostonGene Tumor Portrait assays, to speed up the development and validation of novel precision medicine strategies.

Europe Gene Expression Analysis in Drug Discovery Market:

Europe is to register a considerable market share during the forecasted period. This is mainly driven by rising demand for personalized medicine and advancements in genomic technologies. On February 2025, Psomagen Inc. has announced the newest improvement, the incorporation of Ultima Genomics’ UG 100 next-generation sequencing. The UG 100 will provide faster run times at a lower cost than existing high throughput sequencing equipment. The Ultima UG 100 will add over 12,000 genomes per year to Psomagen’s existing fleet of high output sequencers, which now totals more than 100,000 genomes per year. UG 100’s variant callers can handle around 40 genomes in 2 hours. The technology has the potential to cut operating expenses while also providing researchers with access to NGS and other multiomic technologies.

Competition Analysis:

The gene expression analysis in drug discovery market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in the gene expression analysis in drug discovery market report are:

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Labcorp Drug Development
• Revvity Inc.
• Oxford Nanopore Technologies Ltd.
• Fluidigm Corporation
• Creative Biolabs
• CD Genomics
• BD Biosciences
• Charles River Laboratories
• Qiagen N.V.
• Eurofins Scientific
• 10X Genomics
• Bio-Rad Laboratories, Inc.

Strategic Developments in Gene Expression Analysis in Drug Discovery Market:

• In June 2025, Mission Bio, a leader in single-cell multiomics solutions for precision medicine, has announced the release of its Single-Cell Genotype and Targeted Gene Expression assay, which expands the Tapestri Platform’s capabilities to become the only commercial solution to provide simultaneous genotype and targeted gene expression profiling from over 10,000 single cells. The multi-modal assay serves three key purposes: understanding treatment resistance, creating next-generation T-cell therapeutics, and enhancing patient selection in clinical development.
• In April 2025, CellFE, a leader in non-viral gene editing technology, has established a strategic partnership with the Harbottle Lab at the German Cancer Research Center (DKFZ) and its spin-off firm, TcellTech. This collaboration intends to promote personalized cell treatment development by integrating CellFE’s Ryva Mechanoporation System and TcellTech’s novel nanoSMAR gene expression DNA vector platform. The two methods, when combined, will address significant obstacles in the efficient use of DNA vectors for cell therapy.
• In March 2024, 10x Genomics, Inc., a leader in single cell and spatial biology, has announced the commercial availability of their Visium HD Spatial Gene Expression product. This technique allows researchers to measure the whole transcriptome from FFPE tissue sections at single-cell resolution.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights of the Gene Expression Analysis in Drug Discovery Market Report:

The Gene Expression Analysis in Drug Discovery market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Product and Service Outlook (Revenue, USD Million; 2022-2032)
  • Reagents and Consumables
    • Assays and Kits
    • Enzymes
    • DNA Chips
    • Others
  • Instruments
    • Polymerase Chain Reaction (PCR)
    • Next Generation Sequencing (NGS)
    • DNA Microarrays
    • Others
  • Service
    • RNA Sequencing Services
    • Bioinformatics Services

• Type Outlook (Revenue, USD Million; 2022-2032)
  • Bulk RNA Sequence
  • Single Cell Analysis
  • Spatial Transcriptomics

• Molecule Type Outlook (Revenue, USD Million; 2022-2032)
  • Small Molecule
  • Biosimilars

• Therapeutic Area Outlook (Revenue, USD Million; 2022-2032)
  • Neurology
  • Diabetes
  • Oncology
  • Others

• Application Outlook (Revenue, USD Million; 2022-2032)
  • Biomarker Discovery
  • Drug Target Identification and Validation 
  • Toxicogenomics 
  • Pharmacogenomics 
  • Others

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Hospital & Clinics
  • Pharmaceutical & Biotech Companies
  • Academic Research Institutes

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Gene Expression Analysis in Drug Discovery market report